HUP0500642A2 - Csökkentett toxicitású ciszplatin készítmények és eljárás alkalmazásukra - Google Patents

Csökkentett toxicitású ciszplatin készítmények és eljárás alkalmazásukra

Info

Publication number
HUP0500642A2
HUP0500642A2 HU0500642A HUP0500642A HUP0500642A2 HU P0500642 A2 HUP0500642 A2 HU P0500642A2 HU 0500642 A HU0500642 A HU 0500642A HU P0500642 A HUP0500642 A HU P0500642A HU P0500642 A2 HUP0500642 A2 HU P0500642A2
Authority
HU
Hungary
Prior art keywords
cisplatin
toxicity
methods
agent
reduces
Prior art date
Application number
HU0500642A
Other languages
English (en)
Inventor
Patrick Fogarty
Original Assignee
Tosk, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tosk, Inc. filed Critical Tosk, Inc.
Publication of HUP0500642A2 publication Critical patent/HUP0500642A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány olyan ciszplatin hatóanyagot alkalmazó eljárásokat bocsátrendelkezésre, amelyek során a gazdát érintő toxicitás csökkentmértékű. A találmány szerinti eljárásokban a gazdának egy ciszplatinhatóanyag hatékony mennyiségét egy találmány szerinti, a ciszplatintoxicitását csökkentő szerrel együtt adagolják. A találmánykészítményekre is vonatkozik a találmány szerinti eljárás gyakorlatimegvalósításához, például olyan gyógyászati készítményekre, amelyeknekcsökkent mértékű a toxicitása, és amelyekben a ciszplatin hatóanyagegy a ciszplatin toxicitását csökkentő szerrel van kombinálva, ez aszer csökkenti a ciszplatin nemkívánt toxicitásának szintjét, miközbenmegtartja a ciszplatin proliferációellenes hatékonyságát. A találmánytárgyát képezik továbbá a találmány szerinti eljárások és készítményekkülönböző betegségállapotok kezelésére való alkalmazási eljárásai is.
HU0500642A 2001-09-24 2002-09-20 Csökkentett toxicitású ciszplatin készítmények és eljárás alkalmazásukra HUP0500642A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32456601P 2001-09-24 2001-09-24
PCT/US2002/029669 WO2003026570A2 (en) 2001-09-24 2002-09-20 Reduced toxicity cisplatin formulations and methods for using the same

Publications (1)

Publication Number Publication Date
HUP0500642A2 true HUP0500642A2 (hu) 2005-11-28

Family

ID=23264163

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0500642A HUP0500642A2 (hu) 2001-09-24 2002-09-20 Csökkentett toxicitású ciszplatin készítmények és eljárás alkalmazásukra

Country Status (18)

Country Link
US (1) US20040258771A1 (hu)
EP (1) EP1435963A4 (hu)
JP (1) JP2005510471A (hu)
KR (1) KR20040048900A (hu)
CN (2) CN101062053A (hu)
AU (1) AU2002334595B2 (hu)
BR (1) BR0212744A (hu)
CA (1) CA2461219A1 (hu)
EA (1) EA007481B1 (hu)
HU (1) HUP0500642A2 (hu)
IL (1) IL160960A0 (hu)
MX (1) MXPA04002707A (hu)
NO (1) NO20041484L (hu)
NZ (1) NZ531936A (hu)
PL (1) PL370867A1 (hu)
SK (1) SK1472004A3 (hu)
WO (1) WO2003026570A2 (hu)
ZA (1) ZA200402229B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008060441A2 (en) 2006-11-09 2008-05-22 Scidose Llc Stable amifostine liquid concentrate
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20100035853A1 (en) * 2008-08-07 2010-02-11 Hyogo College Of Medicine Method for preventing or treating cisplatin-induced nephrotoxicity
US20120315324A1 (en) * 2010-02-05 2012-12-13 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
CN103044338B (zh) * 2012-12-12 2016-08-03 天津医科大学总医院 miR-21小分子抑制剂及应用
US11554138B2 (en) 2015-07-16 2023-01-17 The University Of Hong Kong Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy
BR112019009616A2 (pt) * 2016-11-11 2019-08-13 Western University Of Health Sciences métodos de tratamento de carcinomas uroteliais do trato superior
CN112574255B (zh) * 2019-09-27 2024-05-10 中国科学院上海有机化学研究所 一类基于有机胂的cdk抑制剂及其制备方法和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310515A (en) * 1978-05-30 1982-01-12 Bristol-Myers Company Pharmaceutical compositions of cisplatin
US4302446A (en) * 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5770576A (en) * 1989-08-30 1998-06-23 Cytran, Inc. Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity
DE4024885C2 (de) * 1990-08-06 2002-07-18 Nattermann A & Cie Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
US5366723A (en) * 1993-03-05 1994-11-22 Istvan Tulok Method of alleviating toxicity originating from treatment with anticancer platinum compounds
JPH06321792A (ja) * 1993-05-18 1994-11-22 Tsumura & Co 副作用軽減剤
US5646011A (en) * 1994-04-08 1997-07-08 Yokoyama; Shiro Cisplatin resistance gene and uses therefor
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5792748A (en) * 1995-06-07 1998-08-11 The General Hospital Corporation Method for inhibiting neoplastic disease in mammals
US5922689A (en) * 1995-09-11 1999-07-13 Unitech Pharmaceuticals, Inc. Cisplatin analogs for cancer treatment
US6077545A (en) * 1995-10-30 2000-06-20 Matrix Pharmaceuticals, Inc. Process and composition for therapeutic cisplatin (CDDP)
PT929293E (pt) * 1996-08-23 2004-03-31 Sequus Pharm Inc Lipossomas contendo um composto de cisplatina
EP0930877B1 (en) * 1996-10-03 2006-04-19 Southern Illinois University D-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
US6187817B1 (en) * 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
KR100530601B1 (ko) * 1996-12-25 2005-11-23 니폰 가야꾸 가부시끼가이샤 시스플라틴 미분말 및 그의 제조방법
US6030783A (en) * 1997-01-31 2000-02-29 Massachusetts Institute Of Technology Photo-potentiation of cisplatin chemotherapy
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6001817A (en) * 1998-01-12 1999-12-14 Unitech Pharmaceuticals, Inc. Pharmaceutical composition comprised of cisplatin, and processes for making and using same
US6074626A (en) * 1998-03-20 2000-06-13 Molecular Radiation Management, Inc. Radioactive cisplatin in the treatment of cancer
ATE268175T1 (de) * 1998-10-22 2004-06-15 Se Young Chong Decursin-enthaltende pharmazeutische zusammensetzungen
US6130245A (en) * 1998-10-26 2000-10-10 Unitech Pharmaceuticals, Inc. Dinuclear platinum complexes as cisplatin analogs for cancer treatment
JP5409981B2 (ja) * 2000-05-15 2014-02-05 セルジーン コーポレイション 癌治療用の組成物および方法

Also Published As

Publication number Publication date
WO2003026570A2 (en) 2003-04-03
PL370867A1 (en) 2005-05-30
CA2461219A1 (en) 2003-04-03
EA200400348A1 (ru) 2005-04-28
SK1472004A3 (en) 2004-10-05
NO20041484L (no) 2004-04-13
IL160960A0 (en) 2004-08-31
AU2002334595B2 (en) 2007-03-01
CN1589149A (zh) 2005-03-02
NZ531936A (en) 2006-10-27
EP1435963A4 (en) 2005-10-26
US20040258771A1 (en) 2004-12-23
CN101062053A (zh) 2007-10-31
JP2005510471A (ja) 2005-04-21
ZA200402229B (en) 2005-03-22
EA007481B1 (ru) 2006-10-27
EP1435963A2 (en) 2004-07-14
WO2003026570A3 (en) 2004-01-22
KR20040048900A (ko) 2004-06-10
BR0212744A (pt) 2005-10-25
MXPA04002707A (es) 2005-06-06

Similar Documents

Publication Publication Date Title
RU2384580C2 (ru) Ингибиторы фосфатидилинозитол-3-киназы
BR0108449A (pt) Formulações de pasta aperfeiçoada
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
EA200600820A1 (ru) Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
IS6557A (is) Blandaðar sjúkdómsmeðferðir úr blóðþrýstingslækkandi efnum og efnum sem hamla æðamyndun
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
MXPA05002814A (es) Formulacion para agentes lipofilicos.
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
HUP9903732A2 (hu) cGMP-szintjét növelő szerek alkalmazása a jóindulatú prosztatatúltengés kezelésére szolgáló gyógyszerkészítmények előállítására
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
DE60231131D1 (de) Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose
HUP0500642A2 (hu) Csökkentett toxicitású ciszplatin készítmények és eljárás alkalmazásukra
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
ATE353231T1 (de) Pharmazeutische zusammensetzungen
WO2005055956A3 (en) Method for improving insulin sensitivity by administering an inhibitor of antitrypsin
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished